Pharmacogenetic Testing for Medication Management.

Inclusion Criteria: 1. Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 90 days ("index PGx test"); 2. Male or female patients 18 years or older who have given their written Informed Consent to participate in a Clinical Study based on voluntary agreement a through explanation of the patient's participation is provided to them. Patients must have adequate reading and writing abilities such that they can comprehend and answer the questions on the patient- completed assessments and Informed Consent Form; 3. Patient was receiving at least one medication known to be associated with allelic variation at the time of the index PGx test), including over-the-counter medications; 5\. Patient has a history of at least one TDAE over the 12-month period preceding receipt of PGx test results, or has experienced inadequate efficacy from a target drug and receiving medical coverage through a private insurance. Exclusion Criteria: 1. Patient is currently hospitalized; 2. Patient's medical and medication history is unavailable over the 90-day period preceding the receipt of PGx testing; 3. Patient is unable to provide an accurate history due to mental incapacity; 4. Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.